Sharma, A., Subudhi, S., Blando, J., Scutti, J., Vence, L., Wargo, J., … Sharma, P. (2018). Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-18-0762 (Original work published 2018)

Ariyan, C., Brady, M., Siegelbaum, R., Hu, J., Bello, D., Rand, J., … Allison, J. (2018). Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 6(2), 189-200. https://doi.org/10.1158/2326-6066.CIR-17-0356

Gao, J., Ward, J., Pettaway, C., Shi, L., Subudhi, S., Vence, L., … Sharma, P. (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308

Morris, V., Salem, M., Nimeiri, H., Iqbal, S., Singh, P., Ciombor, K., … Eng, C. (2017). Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. The Lancet. Oncology, 18(4), 446-453. https://doi.org/10.1016/S1470-2045(17)30104-3